The cell membrane-coating strategy has opened new opportunities for the development of biomimetic and multifunctional drug delivery platforms. Recently, a variety of gold nanoparticles, which can combine with blood cell membranes, have been shown to provide an effective approach for cancer therapy. Meanwhile, this class of hybrid nanostructures can deceive the immunological system to exhibit synergistic therapeutic effects. Here, we synthesized red blood cell (RBC) and platelet membrane-coated gold nanostars containing curcumin (R/P-cGNS) and evaluated whether R/P-cGNS had improved anticancer efficacy. We also validated a controlled release profile under near-infrared irradiation for the ability to target melanoma cells and to have an immunomodulatory effect on macrophages. RBC membrane coating provided selfantigens; therefore, it could evade clearance by macrophages, while platelet membrane coating provided targetability to cancer cells. Additionally, the nutraceutical curcumin provided anticancer and anti-inflammatory effects. In conclusion, the results presented in this study demonstrated that R/P-cGNS can deliver drugs to the target region and enhance anticancer effects while avoiding macrophage phagocytosis. We believe that R/P-cGNS can be a new design of the cell-based hybrid system for effective cancer therapy.
INTRODUCTION
Cell membranes are useful materials that are often employed in the drug delivery field. Inspired by their nature, many approaches to developing multifunctional drug carriers have been reported, which include so-called biomimetic drug delivery systems (Banskota et al., 2017) . For instance, coating a variety of synthetic materials, including carbon, poly (lactic-co-glycolic acid) (PLGA), graphene, and gold nanoparticles with natural cell membranes such as those of cancer cells, stem cells, white blood cells, red blood cells (RBCs), and platelets (PLTs) have been widely used in the drug delivery field (Gao et al., 2017; Zhang et al., 2018a; Zhen et al., 2019) . Cell membranes share properties with lipid-based nanoparticles and leverage these biological functions. Moreover, membranecoated biomimetic drug delivery systems can load hydrophobic drugs into the phospholipid bilayer without any conjugation just as many lipid-based nanoparticles can. Hence, the membrane-coating strategy not only significantly increases the biocompatibility of nanoparticles but also improves their bioavailability (Fang et al., 2018) .
Photothermal therapy (PTT) is a relatively non-invasive and safer method compared with conventional cancer treatment strategies due to its high accuracy (Okuno et al., 2013) . Among PTT agents, gold nanoparticles are a promising candidate for cancer therapy because they are highly adjustable to surface modification, particle size, particle shape, and uniformity (Huang et al., 2007) . All of these properties offer a variety of functions in biological systems and influence treatment efficacy. Gold nanoparticles are usually modified with polyethylene glycol (PEG) to enhance solubility, stability, and immune escape; however, there are many concerns about the PEGylation technique (Knop et al., 2010; Ishida and Kiwada, 2013; Zhang et al., 2017) . PEGylation can activate the human complement system after repetitive administration, and the presence of anti-PEG antibodies may limit the therapeutic efficacy of gold nanoparticles. Instead of PEGylation, RBC membranes can offer a greater ability for immune escape (Piao et al., 2014) , as RBC membrane proteins act as immunomodulatory antigens that help to avoid phagocytosis.
The exact mechanism of high temperature-mediated killing of tumor cells remains unclear. PTT can cause cellular necrosis at temperatures above 42 • C, which can also be highly toxic to normal cells around the tumor region (Zhang et al., 2018b) . Eventually, other approaches to broaden the application of gold nanoparticles are needed. For instance, the biomimetic strategy can combine PTT with currently available anticancer therapies such as chemotherapy to achieve improved therapeutic outcomes with increased safety (Hua et al., 2017) . Biomimetic gold nanoparticles can enhance therapeutic efficacy under lower temperatures. Natural cell membranes are vulnerable to temperature changes, allowing the chemotherapeutics to be released from the membranes as the temperature is slightly increased (Roach et al., 2013; Kwon et al., 2015; Ebrahimi et al., 2018) . This not only maximizes therapeutic effects but also prevents injury to adjacent healthy cells.
Considering its systemic toxicity and highly selective delivery, PTT agents are often used via intratumoral injection, and then subjected to irradiation by an external near-infrared irradiation (NIR) laser to generate heat for effective photothermal killing (Zhang et al., 2015) . However, clinical applications of traditional PTT could be limited by the unpredictable tumoral nature; thus, a systemic approach is very meaningful. Well-fabricated gold nanoparticles can be localized to the desired tumor region via passive targeting, meaning the photothermal effect aids tumor penetration as well as killing the tumor (Zou et al., 2016) . Nevertheless, gold nanoparticles without any functionalization are incapable of active targeting. To solve this problem, PLT membranes have been used to offer direct targeting (Jing et al., 2018) . It has been demonstrated that PLT can recognize cancer cells as well as adhere to the damaged tumor vasculature or rapidly growing tumor vessels (Gay and Felding-Habermann, 2011; Goubran et al., 2014; Ortiz-Otero et al., 2018) . Based on these rationales, in this study, we demonstrate the influence of versatile gold nanoparticles on therapeutic effects, cancertargeting effects in melanomas, and immune escape ability from macrophages.
MATERIALS AND METHODS

Preparation of Gold Nanostars (GNS)
Gold nanostars were prepared using a seed-mediated growth method (Yuan et al., 2012) . All glassware and stirring bars were treated with aqua regia, rinsed with distilled water, and dried at 100 • C. The seed gold nanoparticles were synthesized through citrate reduction of HAuCl 4 . Trisodium citrate dihydrate solution (1 wt%, 15 mL) was added to a reaction flask containing the boiling HAuCl 4 ·3H 2 O solution (1 mM, 100 mL) under vigorous stirring. The reaction solution was heated for 15 min until the color turned from colorless to light red. Then, the solution was cooled and filtered using a 0.45 µM cellulose acetate membrane syringe filter. For GNS synthesis, the seed solution (30 µL) was added to the 20 mL glass vial containing the HAuCl 4 ·3H 2 O (0.25 mM, 10 mL) and HCl (1 M, 20 µL) solutions at room temperature (RT) under stirring. Then, AgNO 3 solution (3 mM, 100 µL) and ascorbic acid (100 mM, 50 µL) were quickly and simultaneously added to the reaction solution. This was stirred for 30 s until the color turned from light red to greenish-blue. The surface of GNS was functionalized with NH 2 -PEG-SH solution (4.5 mM, 200 µL). Finally, PEGylated GNS were centrifuged at 4,500 × g for 15 min, and then dispersed in distilled water.
Preparation of Blood Cell Membrane-Coated GNS
Fresh mouse blood was collected from C57BL/6 mice by cardiac puncture for RBC and PLT isolation. RBCs and PLTs derived from this blood source were used in this study. To isolate RBCs and PLTs, the blood sample was centrifuged at 100 × g for 20 min at RT. Then, the blood was separated into PLT-rich plasma (PRP) supernatant and RBC sediment. The resulting PRP was centrifuged again at 100 × g for 20 min at RT to remove remaining blood cells. Then, PLTs were pelleted by centrifugation at 800 × g for 20 min at RT, and the pelleted PLTs were resuspended in PBS (pH 7.4). PLT membranes were prepared by a repeated freeze-thaw method, and the resultant PLT membrane solution was centrifuged at 14,000 × g for 20 min. After washing three times, final PLT membrane samples were obtained and used to coat GNS.
Red blood cell ghosts (RBCs without hemoglobin) were prepared by treating RBCs in a hypotonic solution. RBC pellets obtained from the previous step were re-suspended in a 25% PBS solution and vigorously mixed by pipetting. RBCs were pelleted by centrifugation at 14,000 × g for 20 min at RT, re-suspended with PBS, and this process was repeated until all hemoglobin was released from the RBCs. RBC membranes were prepared by sonication, and the final RBC membrane samples in PBS were used to coat GNS.
Curcumin was dissolved in methanol and then diluted in a 1:100 ratio of a warm PBS solution. RBC and PLT membranes (RBC/PLT; 0.5:0.5 protein w/w ratio) were mixed with 500 µL of curcumin in PBS (0.1 mg/mL). The resultant mixture was sonicated in a water bath for 5 min and subsequently extruded 10 times through an 800 nm membrane filter using an Avanti extruder to encapsulate curcumin. Then, GNS were mixed with the blood cell membranes and kept for 30 min at RT. After incubation, the mixture was extruded 10 times through a 400 nm membrane filter to coat the GNS with blood cell membranes containing curcumin. The coated GNS were subsequently centrifuged at 4,000 × g for 15 min to remove excess blood cell membranes. These RBC and PLT membrane-coated GNS containing curcumin (R/P-cGNS) were then characterized and used for further experimentation.
Physicochemical Characteristics of R/P-cGNS
The morphology of R/P-cGNS were characterized using a transmission electron microscope (JEOL-2100F, JEOL Ltd., Tokyo, Japan). An aliquot of R/P-cGNS solution was placed on a carbon-coated 400 mesh copper grid for 10 min. The solution was removed by gentle tapping, washed two times, negativestained with uranyl acetate, and then dried. The prepared samples on the grid were observed with an electron microscope. The hydrodynamic size and zeta potentials of R/P-cGNS were measured using a Malvern Zetasizer (Nano ZS, Malvern Instruments Ltd., Malvern, United Kingdom). The absorption spectra of each component of R/P-cGNS were also measured in a microplate reader to verify successful membrane coating and curcumin encapsulation. The curcumin encapsulation rate and release profiles were measured for 1 h after sample incubation with 1% SDS to fully isolate curcumin from the membrane. Thereafter, the absorbance of the solution was measured using UV-vis spectrophotometer (Infinite M200 Pro, TECAN Group Ltd., Männedorf, Switzerland) at a wavelength of 424 nm (Supplementary Figure S1 ).
Photothermal Properties the Prepared Materials
Thermographic images of water, blood cell membranes, GNS, and R/P-cGNS were captured to verify photothermal conversion. Each sample was exposed to an 808 nm NIR laser for 5 min, and the temperature changes were recorded at every time-point using a digital thermal image detector. Subsequently, NIR lightcontrolled drug release was also evaluated following 808 nm NIR laser irradiation. The curcumin release from R/P-cGNS (50 ppm) in a glass tube was monitored with and without irradiation. The concentration of released curcumin was calculated using a spectrophotometer at 424 nm.
Flow Cytometry and Confocal Microscopy
Quantitative cellular uptake of different drug formulations (free curcumin, R-cGNS, P-cGNS, and R/P-cGNS) in B16-BL6 melanoma cells (ATCC, Manassas, VA, United States) was verified by flow cytometry (BD Accuri C6 Plus; BD Bioscience, San Diego, CA, United States) 3 h after treatment. Subsequently, the drug distribution pattern of curcumin in the cancer cells was observed by confocal fluorescence microscopy (BZ-8000; KEYENCE, Osaka, Japan) using the same conditions. Co-localization of R/P-cGNS and lysosome was confirmed by staining LysoTracker Green DND-26 (Invitrogen, Carlsbad, CA, United States) 3 h after treatment. The laser irradiation group was exposed to NIR laser for 5 min after 1 h of treatment, and then incubated for an additional 2 h.
In vitro Cytotoxicity
B16-BL6 cells (5 × 10 3 , 100 µL) were incubated in 96-well plates at 37 • C with 5% CO 2 for 24 h. Then, media with the different drug formulations (curcumin, GNS, R-cGNS, P-cGNS, and R/P-cGNS) were added to the wells. Following drug addition, each condition was treated with and without NIR laser irradiation and further incubated for 72 h. Cellular viability was measured by the MTT assay at 595 nm. The cytotoxicity of GNS and free curcumin on B16-BL6 cells was also tested.
For colony formation assays, B16-BL6 cells (5 × 10 2 cells, 200 µL) were prepared in tubes and treated with different drug formulations. Each condition was immediately exposed with and without NIR laser irradiation and seeded onto six-well plates. After 24 h, the cells were replaced with fresh medium and incubated for 10 days. After the 10-day culture, visible colonies were fixed with 100% methanol, washed with water, stained with 0.5% crystal violet in 25% methanol for 5 min, and washed with water until the excess dye was removed. After drying overnight, colony numbers were assessed visually. Pictures were taken using a digital camera.
Gold Uptake by Macrophages
The immune escaping ability of various GNS formulations from phagocytosis was verified in the murine macrophage cell line, RAW264.7. To observe the nano-sized gold nanoparticles in the cytoplasm, a high concentration of GNS (100 ppm) was used to treat the macrophages, and their morphological changes and gold uptake were subsequently visualized with an optical microscope 4 h after incubation. The macrophages were fixed with 100% methanol and stained with 0.5% crystal violet in 25% methanol. Lipopolysaccharide (LPS) was used as a positive control.
To measure the actual uptake rate of gold atoms by macrophages, inductively coupled plasma-mass spectrometry (ICP-MS; iCAP 7000 Series, Thermo Fisher Scientific, Waltham, MA, United States) was used. Macrophages treated with each GNS sample 4 h after incubation were dissolved in aqua regia (a 3:1 mixture of hydrochloride and nitric acid), and the gold concentration was calculated compared with a gold standard curve.
Immune Responses
RAW264.7 cells were seeded in 6-well plates at a density of 5 × 10 5 cells/mL and incubated for 24 h. After incubation, the cells were treated with various concentrations of curcumin or various formulations of GNS for 2 h, and then stimulated with LPS (500 ng/mL) for an additional 6 h. A total of 1 mL of the cell culture supernatant was collected and levels of TNF-α, MCP-1, and IL-6 were detected using commercial mouse ELISA kits (430904, 432704, and 431304; BioLegend, San Diego, CA, United States) in accordance with the manufacturer's protocols.
Animal Study
The experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of Kumamoto University (#A28-003) and conducted following protocols in accordance with the guidelines.
Statistical Analysis
Data were analyzed by one-way or two-way analysis of variance (ANOVA) using Prism 7 (GraphPad Software, Inc., La Jolla, CA, United States). In all cases, the significance level was set at * p < 0.05, * * p < 0.01, and * * * p < 0.001 or † p < 0.05, and † † † p < 0.001 between the experimental groups; n.s. represents no significant difference.
RESULTS
Preparation and Characterization of R/P-cGNS
To prepare R/P-cGNS, we first extracted cell membranes from RBCs and PLTs. Given the hydrophobicity profile of curcumin, it was encapsulated into the prepared blood cell membranes. Then the GNS were coated with these membranes via electrostatic interaction to fabricate R/P-cGNS containing curcumin as illustrated in Figure 1A and Supplementary Figure  S2 . The surface modification of the gold nanoparticles using each functional blood cell membrane brought different advantages such as immune escape ability and cancer-targeting. Therefore, we used the different GNS designs for ease of comparison.
In the following study, GNS was used as the control. The functions of R-cGNS and P-cGNS were compared to R/P-cGNS; designs without curcumin were R-GNS, P-GNS, and R/P-GNS, respectively. TEM observations were used to characterize the morphology of GNS and R/P-cGNS. After coating with blood cell membranes, R/P-cGNS showed a uniform star shape with a membrane shell around GNS, indicating successful membrane coating (Figure 1B) . SDS-PAGE protein analysis of P-cGNS, R-cGNS, and R/P-cGNS also proved that blood cell membranes were successfully coated onto GNS (Supplementary Figure S3) . As shown in Figure 1C , the average hydrodynamic diameters of R/P-cGNS were slightly increased from 134.1 ± 1.2 nm in diameter to 162.1 ± 3.0 nm in diameter after membrane coating. The pattern of particle size distribution and the low polydispersity index (PDI) of 0.26 clearly verified no aggregation of particles (Supplementary Figure S4) . Additionally, in response to the serum proteins in the 10% FBS solution, the particle size of R/P-cGNS remained constant, which implies that the particles possess colloidal stability (Supplementary Figure S5) . The surface charge of R/P-cGNS (−23.7 ± 0.3 mV) decreased by over 50 mV compared with bare GNS (31.9 ± 0.2 mV) after membrane coating because the outer membrane surface exhibited a negative surface charge (Figure 1C) . Additionally, the characteristic peaks of GNS (814 nm), blood cell membranes (300-700 nm, or 950-1000 nm), and curcumin (424 nm) in absorption spectra demonstrated that the membrane coating and drug encapsulation of R/R-cGNS had been successful (Figure 1D) . The drug encapsulation efficiency and drug loading capacity were 71.6 ± 12.5% and 4.8 ± 0.8%, respectively (Supplementary Figure S6) .
Photothermal Properties and Drug Release of R/P-cGNS
To investigate the effect of NIR laser irradiation on R/P-cGNS, temperature changes were measured using a digital thermal image detector (Figure 2A) . There was no significant temperature change of water or RBC/platelet membranes over time, while the temperature curves of GNS and R/P-cGNS exhibited a rising pattern, which clearly indicated that GNS could generate hyperthermia under NIR irradiation and that membrane coating did not affect the photothermal effects of the GNS (Figure 2B) . Within 2 min, the temperature increased to more than 42 • C, which can induce photothermal therapeutic effects for cancer. The cumulative release profile of the drug suggested that hyperthermia can make blood cell membranes unstable, which then released the encapsulated curcumin. Driven by laser irradiation and the subsequent temperature increase, curcumin was rapidly released from R/P-cGNS, while no significant drug release was detected without laser irradiation (Figure 2C) . These results indicated that R/P-cGNS could provide a controlled drug release under NIR laser irradiation, achieving both the expected photothermal and chemotherapeutic effects.
Targeting Ability of R/P-cGNS B16-BL6 cells were incubated with an equal amount of curcumin, which was loaded in different GNS designs, and their drug delivery efficiencies on cancer cells were compared by flow cytometry (Figure 3A) . The cells treated with curcumin exhibited a yellow color and we observed a distinct peak that was shifted to the right. A comparative analysis of curcumin uptake in B16-BL6 cells revealed that free curcumin showed the highest mean fluorescence intensity (MFI) value because it rapidly diffused into the cells in vitro (Figure 3B) . GNS with PLT membrane represented a higher MFI value compared with that of GNS with a RBC membrane only, which was a result of the cancertargeting ability. The MFI value of P-cGNS was slightly higher than that of R/P-cGNS, but there was no significant difference, which is assumed to be because PLT membrane contents for P-cGNS were twice as high as that of R/P-cGNS. These results indicated that R/P-cGNS has a targeting ability comparable to P-cGNS on cancer cells.
Cellular Uptake and Distribution Profile of R/P-cGNS
To evaluate the cellular uptake of curcumin, the fluorescence properties after free curcumin, P-cGNS, R-cGNS, and R/P-cGNS treatment of B16-BL6 cells were examined by confocal microscopy (Figure 3C) . Significant cellular uptake of curcumin was observed in the free curcumin-treated group, and it was evenly distributed in the cytoplasm; few R-cGNS could bind to cancer cells, and the fluorescent signal was weak. Conversely, when curcumin was delivered by P-cGNS or R/P-cGNS, the signal was relatively strong. Moreover, strong dotshaped yellow fluorescence signals of curcumin were observed at the corresponding locations of GNS in bright field imaging, which demonstrates that the GNS was successfully attached to cancer cells (Supplementary Figure S7) . Unlike free curcumin which is internalized into the cytoplasm through cytosolic diffusion, to clarify the intracellular uptake of R/P-cGNS, we tracked the location of R/P-cGNS by fluorescence labeling of the cellular compartment; R/P-cGNS was entrapped into endosome/lysosome 3 h after treatment, while curcumin could be successfully released from the vesicles by laser irradiation (Supplementary Figure S8) .
Cytotoxic Properties of R/P-cGNS
Prior to proceeding to cytotoxicity test, the biocompatibility of GNS and the IC 50 value of curcumin was evaluated. B16-BL6 cells were treated with bare GNS for 48 h, and the cytotoxicity of GNS was negligible even at the concentration of 30 ppm (Supplementary Figure S9) . The IC 50 value of curcumin was 32.6 µM as verified under the same condition ( Supplementary  Figure S10) . Based on these results, the chemo/photothermal cytotoxicity potential of all GNS formulations without or with laser irradiation was evaluated by the MTT assay (Figure 4A) . B16-BL6 cells were treated with curcumin at the IC 50 concentration for 48 h. The free curcumin treatment group showed a considerable chemotherapeutic effect compared with the other groups, and NIR laser irradiation showed only a negligible therapeutic effect. Conversely, all groups irradiated by NIR laser after treatment of GNS formulations displayed significant cell death. The targetability of PLT membranes was further investigated and compared with R-cGNS. P-cGNS and R/P-cGNS showed higher cytotoxicity than R-cGNS. The cell viability was 36.4% for P-cGNS and 42.9% for R/P-cGNS, which was even lower than that of free curcumin (48.2%).
Long-Term Therapeutic Effects of R/P-cGNS
Colony formation assays show only the metabolically active and viable cells after over 10-day incubation; thus, this is a valuable tool for overcoming the limitations of short-period evaluations using the MTT assay. Figure 4B shows the long-term therapeutic effects of GNS formulations and revealed the inhibition of colony formation of B16-BL6 cancer cells. A similar pattern to the MTT assay results was observed in the colony formation assays. Together these results indicated that R/P-cGNS could combine the photothermal effects of gold nanoparticles with the chemotherapeutic effects of curcumin under laser stimuli, leading to improved therapeutic effects in short-and longterm treatments.
Immune Escaping Ability of R/P-cGNS
Each of the GNS formulations was used to evaluate the phagocytic ability of macrophages. RAW264.7 murine macrophages were incubated with GNS formulations, and then intracellular gold nanoparticles were observed using light microscopy (Figure 5A) . High concentrations of intracellular gold nanoparticles were observed as black spots in the cytoplasm of the cells. We found that macrophages treated with GNS accumulated more gold than blood cell membrane-coated GNS (Figure 5B) . The surface coating of GNS with RBC membranes significantly inhibited phagocytosis (2.7-fold, ***p < 0.001) compared with GNS with PLT membranes. Additionally, R/P-cGNS (1.7-fold, ***p < 0.001) significantly improved the immune escaping ability to a similar extent as R-cGNS. These results indicated that R/P-cGNS had a comparable immune escaping ability to R-cGNS for macrophages. As shown in Figure 5A , control macrophages were round, whereas, after LPS stimulation, the macrophages changed into a spiky shape, suggesting that they were activated and ready to engulf foreign materials. This macrophage activation was also induced after GNS treatment. In general, activated macrophages produce cytokines such as TNF-α, IL-6, and MCP-1. The results of counting the number of activated macrophages and measuring the levels of pro-inflammatory cytokines clearly showed that R/P-cGNS, as well as R-cGNS, inhibited macrophage activation and balanced inflammatory responses (Figures 5C, 6) .
DISCUSSION
There has been sufficient success in fabricating gold nanoparticles over the past decade that they can no longer be called a new attempt. However, combining the functionality of natural cell membranes from different origins has been insufficiently studied. In this work, we coated GNS with RBC and PLT membranes to simultaneously take advantage of immune evasion and cancer cell targeting abilities. The results of our experiments provide the underlying data for using RBC and PLT membranes together. We confirmed that RBC and PLT membrane-coated GNS could improve cancer targeting, alleviate immune responses, escape phagocytosis, and enhance anticancer effects. The use of gold nanoparticle coated with only a single membrane was slightly more effective than R/P-cGNS in some experiments; however, R/P-cGNS retained the functionality of both blood cell membranes. Considering the complex biological environment, R/P-cGNS might warrant further animal studies (Nel et al., 2009) . The major immunomodulatory protein on the surface of blood cells is CD47, which is well known to give a "don't eat me" signal (Burger et al., 2012) . Although CD47 antigen, an important "self-recognition" protein, not only exists on RBCs, it is highly expressed on the surface of RBCs, helping to circulate RBCs in the bloodstream. The CD47 antigen enables cells to avoid phagocytosis by binding to the inhibitory receptor signal regulatory protein alpha (SIRPα) on macrophages, unlike PEGylation, which is a commonly used method to conceal the properties of nanoparticles by the hydration effect of PEG (Rao et al., 2015) . According to the study by Hu et al. (2011) RBC membranes camouflaged nanoparticles have a prolonged circulation time in the blood compared with PEGylated nanoparticles by deceiving the immune system. In this study, we also found that RBC membrane coating can help to escape from macrophage phagocytosis; furthermore, the CD47-SIRPα interaction can directly regulate immune responses (Figures 5, 6) . Additionally, curcumin can act as an anticancer drug as well as an anti-inflammatory drug; thus, it can induce immunosuppression even when R/P-cGNS are caught through macrophage phagocytosis (Supplementary Figure S11 ; Fadus et al., 2017) . Over the past quarter-century, curcumin has attracted great attention due to its multitude of functions. Extensive clinical trials have addressed the efficacy of this versatile drug in cancer patients (Gupta et al., 2013) . Despite considerable therapeutic efficacy, poor bioavailability has been a limitation to its use in humans. Since curcumin is sparingly soluble in aqueous solution at approximately 0.1 mg/mL, efforts are needed to improve the solubility of curcumin. According to Kurien et al. (2007) , the solubility of curcumin in water could be maximized by dissolving first in methanol and then diluting with water or even using heat. Furthermore, the use of the cell membrane can improve the bioavailability of curcumin using lipid-based nanoparticles that capture hydrophobic drugs, and also allow intravenous injection (Kim et al., 2018) . We also showed that curcumin has additional therapeutic benefits by using R/P-cGNS for cancer therapies including photothermal effects, controlled drug release at elevated temperature, and the targeting of cancer cells through PLTs. Recently, many trials have been implemented to study the use of the tumor-targeting properties of PLTs (Dehaini et al., 2017; Wang et al., 2019) . PLTs primarily play an important role in hemostasis; the initial stage of hemostasis begins with the binding of activated platelets to the damaged vessels exposing von Willebrand factor (vWF), which prevents excessive bleeding (Yun et al., 2016) . Thereafter, membrane proteins such as glycoprotein IIb/IIIa and glycoprotein Iba specifically bind to biomolecules like P-selectin, CD44, and vWF (Hu et al., 2015) . These biomolecules are highly expressed in some types of cancer, including melanoma, hematoma, and osteosarcoma (Bauer et al., 2015) . The interaction between the platelets and cancer cells has been reported to be related to thrombus formation and cancer metastasis (Mojiri et al., 2017) . We found a therapeutic potential of R/P-cGNS on melanoma cells in particular; the melanoma cancer cell line B16-BL6 is reported to be effective in the treatment of curcumin and also to have a high expression level of vWF, which is the main target of PLTs. The results in Figure 3 reflect that R/P-cGNS have tumor-targeting ability because of the PLT membrane.
In this study, we prepared biomimetic GNS, R/P-cGNS, that were very delicately designed. Although R/P-cGNS have shown promising potential as a therapeutic strategy, it is still confronted with many difficulties in the biological environment.
However, we are anticipating interesting results from star-shaped biomimetic gold nanoparticles, not sphere-or rod-shaped, from in vivo systems. This work was inspired by the features of PLTs, which normally circulate in the blood with a spherical shape in an inactive state and function only when they are activated and transform into a star shape (Jennings, 2009) . We hypothesize that our results are related to recent findings regarding the correlation between the shape of the particles and their dynamic flow in the blood. It has already been reported that particle shape can affect particle bio-distribution and improve drug delivery (Tan et al., 2013) . Further research will be needed in animal models or hemodynamic studies to explain these findings.
CONCLUSION
To find some evidence for the potential of GNS in a biological environment, R/P-cGNS were investigated in this study. R/P-cGNS provide a controlled release profile, better targeting to cancer cells, immune escape, and enhanced therapeutic effects in vitro. The combination therapy of curcumin under NIR laser irradiation inhibited tumor growth. We also revealed that curcumin can provide anti-inflammatory effects on macrophages. Despite these advantages of R/P-cGNS, our system still requires further evaluation in vivo. As RBCs and PLTs are natural sources isolated from the blood, they might provide promising results for future preclinical trials. In conclusion, this study demonstrated that the newly developed blood cell membrane-coated GNS could be a good candidate for a biomimetic system that is ideal for cancer therapy.
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